Overview |
bs-13109R |
ETEA Polyclonal Antibody |
WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
Mouse |
Human, Rat, Sheep, Horse, Chicken |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic peptide derived from human ETEA |
81-180/445 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
23197 |
Cytoplasm |
AI462440; expressed in T cells and eosinophils in atopic dermatitis; faf2; FAF2_HUMAN; Fas associated factor family member 2; FAS-associated factor 2; KIAA0887; Protein ETEA; Protein expressed in T cells and eosinophils in atopic dermatitis; Protein expressed in T-cells and eosinophils in atopic dermatitis; UBX domain containing 8; UBX domain protein 3B; UBX domain-containing protein 3B; UBX domain-containing protein 8; UBXD8; UBXN3B. |
ETEA is a 445-amino acid protein associated with atopic dermatitis (AD), a chronic noncontagious relapsing inflammatory skin disease characterized by eczematous skin lesions and also referred to as eczematous dermatitis. Other atopic diseases such as hay fever, asthma and conjunctivitis often occur along with AD. ETEA shows higher expression in T cells and eosinophils of patients with AD than in T cells and eosinophils of unaffected individuals. T cells are influential in the regulation of the inflammatory process of this disease. The persistence of jAD is attributed to dysregulated apoptosis in T cells, eosinophils, and keratinocytes. ETEA may be involved in the resistance to apoptosis in T cells and eosinophils of AD patients. |
Application Dilution |
WB |
1:300-5000 |
ELISA |
1:500-1000 |
IHC-P |
1:200-400 |
IHC-F |
1:100-500 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |
ICC |
1:100-500 |